139 related articles for article (PubMed ID: 36255624)
1. Evaluation of Small-Molecule HDAC Inhibitors Through In Vitro and In Cellulo Approaches.
Nawar N; Garcha HK; Sedighi A; de Araujo ED; Gunning PT
Methods Mol Biol; 2023; 2589():157-177. PubMed ID: 36255624
[TBL] [Abstract][Full Text] [Related]
2. Current trends in development of HDAC-based chemotherapeutics.
Cheshmazar N; Hamzeh-Mivehroud M; Nozad Charoudeh H; Hemmati S; Melesina J; Dastmalchi S
Life Sci; 2022 Nov; 308():120946. PubMed ID: 36096240
[TBL] [Abstract][Full Text] [Related]
3. Oral administration of the pimelic diphenylamide HDAC inhibitor HDACi 4b is unsuitable for chronic inhibition of HDAC activity in the CNS in vivo.
Beconi M; Aziz O; Matthews K; Moumné L; O'Connell C; Yates D; Clifton S; Pett H; Vann J; Crowley L; Haughan AF; Smith DL; Woodman B; Bates GP; Brookfield F; Bürli RW; McAllister G; Dominguez C; Munoz-Sanjuan I; Beaumont V
PLoS One; 2012; 7(9):e44498. PubMed ID: 22973455
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory selectivity among class I HDACs has a major impact on inflammatory gene expression in macrophages.
Cao F; Zwinderman MRH; van Merkerk R; Ettema PE; Quax WJ; Dekker FJ
Eur J Med Chem; 2019 Sep; 177():457-466. PubMed ID: 31181405
[TBL] [Abstract][Full Text] [Related]
5. Rational Design and Development of HDAC Inhibitors for Breast Cancer Treatment.
Mody D; Bouckaert J; Savvides SN; Gupta V
Curr Pharm Des; 2021; 27(45):4610-4629. PubMed ID: 34533439
[TBL] [Abstract][Full Text] [Related]
6. The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
Negmeldin AT; Pflum MKH
Bioorg Med Chem Lett; 2017 Aug; 27(15):3254-3258. PubMed ID: 28648461
[TBL] [Abstract][Full Text] [Related]
7. Profiling technologies for the identification and characterization of small-molecule histone deacetylase inhibitors.
Liao D
Drug Discov Today Technol; 2015 Nov; 18():24-8. PubMed ID: 26723889
[TBL] [Abstract][Full Text] [Related]
8. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
Khan N; Jeffers M; Kumar S; Hackett C; Boldog F; Khramtsov N; Qian X; Mills E; Berghs SC; Carey N; Finn PW; Collins LS; Tumber A; Ritchie JW; Jensen PB; Lichenstein HS; Sehested M
Biochem J; 2008 Jan; 409(2):581-9. PubMed ID: 17868033
[TBL] [Abstract][Full Text] [Related]
9. From natural products to HDAC inhibitors: An overview of drug discovery and design strategy.
Qiu X; Zhu L; Wang H; Tan Y; Yang Z; Yang L; Wan L
Bioorg Med Chem; 2021 Dec; 52():116510. PubMed ID: 34826681
[TBL] [Abstract][Full Text] [Related]
10. Novel Approaches Towards Designing of Isoform-Selective Inhibitors Against Class II Histone Deacetylases: The Acute Requirement for Targetted Anticancer Therapy.
Ganai SA
Curr Top Med Chem; 2016; 16(22):2441-52. PubMed ID: 26873193
[TBL] [Abstract][Full Text] [Related]
11. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells.
Dejligbjerg M; Grauslund M; Litman T; Collins L; Qian X; Jeffers M; Lichenstein H; Jensen PB; Sehested M
Mol Cancer; 2008 Sep; 7():70. PubMed ID: 18789133
[TBL] [Abstract][Full Text] [Related]
13. Structurally Diverse Histone Deacetylase Photoreactive Probes: Design, Synthesis, and Photolabeling Studies in Live Cells and Tissue.
Aboukhatwa SM; Hanigan TW; Taha TY; Neerasa J; Ranjan R; El-Bastawissy EE; Elkersh MA; El-Moselhy TF; Frasor J; Mahmud N; McLachlan A; Petukhov PA
ChemMedChem; 2019 Jun; 14(11):1096-1107. PubMed ID: 30921497
[TBL] [Abstract][Full Text] [Related]
14. Effects of novel HDAC inhibitors on urothelial carcinoma cells.
Kaletsch A; Pinkerneil M; Hoffmann MJ; Jaguva Vasudevan AA; Wang C; Hansen FK; Wiek C; Hanenberg H; Gertzen C; Gohlke H; Kassack MU; Kurz T; Schulz WA; Niegisch G
Clin Epigenetics; 2018 Jul; 10(1):100. PubMed ID: 30064501
[TBL] [Abstract][Full Text] [Related]
15. Identification of potent HDAC 2 inhibitors using E-pharmacophore modelling, structure-based virtual screening and molecular dynamic simulation.
Pai P; Kumar A; Shetty MG; Kini SG; Krishna MB; Satyamoorthy K; Babitha KS
J Mol Model; 2022 Apr; 28(5):119. PubMed ID: 35419753
[TBL] [Abstract][Full Text] [Related]
16. Selective Inhibitors of Histone Deacetylase 10 (HDAC-10).
Pojani E; Barlocco D
Curr Med Chem; 2022; 29(13):2306-2321. PubMed ID: 34468295
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of quinoline derivatives as HDAC class I inhibitors.
Chen C; Hou X; Wang G; Pan W; Yang X; Zhang Y; Fang H
Eur J Med Chem; 2017 Jun; 133():11-23. PubMed ID: 28371677
[TBL] [Abstract][Full Text] [Related]
18. Human HDAC isoform selectivity achieved via exploitation of the acetate release channel with structurally unique small molecule inhibitors.
Whitehead L; Dobler MR; Radetich B; Zhu Y; Atadja PW; Claiborne T; Grob JE; McRiner A; Pancost MR; Patnaik A; Shao W; Shultz M; Tichkule R; Tommasi RA; Vash B; Wang P; Stams T
Bioorg Med Chem; 2011 Aug; 19(15):4626-34. PubMed ID: 21723733
[TBL] [Abstract][Full Text] [Related]
19. Natural products as zinc-dependent histone deacetylase inhibitors.
Tan S; Liu ZP
ChemMedChem; 2015 Mar; 10(3):441-50. PubMed ID: 25581683
[TBL] [Abstract][Full Text] [Related]
20. An update on the emerging approaches for histone deacetylase (HDAC) inhibitor drug discovery and future perspectives.
Su M; Gong X; Liu F
Expert Opin Drug Discov; 2021 Jul; 16(7):745-761. PubMed ID: 33530771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
